MorphoSys Sees Unusually Large Options Volume (NASDAQ:MOR)

MorphoSys AG (NASDAQ:MOR) saw some unusual options trading on Thursday. Stock investors bought 5,232 put options on the company. This is an increase of 342% compared to the typical volume of 1,183 put options.

MorphoSys Trading Down 10.8 %

MOR stock opened at $6.20 on Friday. MorphoSys has a fifty-two week low of $3.17 and a fifty-two week high of $8.67. The business’s 50 day moving average price is $7.20 and its two-hundred day moving average price is $7.19. The company has a current ratio of 3.57, a quick ratio of 3.27 and a debt-to-equity ratio of 7.56.

Institutional Trading of MorphoSys

A number of hedge funds have recently made changes to their positions in the stock. UBS Group AG lifted its holdings in shares of MorphoSys by 122.7% during the 3rd quarter. UBS Group AG now owns 5,141 shares of the company’s stock valued at $26,000 after buying an additional 2,832 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of MorphoSys in the 3rd quarter worth $40,000. BNP Paribas Arbitrage SNC increased its stake in shares of MorphoSys by 9,680.0% in the 2nd quarter. BNP Paribas Arbitrage SNC now owns 9,780 shares of the company’s stock worth $73,000 after purchasing an additional 9,680 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of MorphoSys in the 2nd quarter worth $53,000. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of MorphoSys in the 3rd quarter worth $97,000.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on MOR. The Goldman Sachs Group raised MorphoSys from a “sell” rating to a “neutral” rating and raised their target price for the stock from $3.50 to $9.25 in a research report on Thursday, September 14th. Morgan Stanley upgraded MorphoSys from an “underweight” rating to an “overweight” rating and lifted their price target for the company from $3.70 to $9.20 in a research report on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat, MorphoSys presently has a consensus rating of “Moderate Buy” and an average price target of $12.08.

MorphoSys Company Profile

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.